E7389

Phase 2Completed
0 watching 0 views this week Active
52
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Soft Tissue Sarcoma

Conditions

Soft Tissue Sarcoma

Trial Timeline

Jan 1, 2007 → Feb 1, 2013

About E7389

E7389 is a phase 2 stage product being developed by Eisai for Soft Tissue Sarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00413192. Target conditions include Soft Tissue Sarcoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (8)

NCT IDPhaseStatus
NCT01432886Phase 1Completed
NCT00413192Phase 2Completed
NCT00326950Phase 1Completed
NCT00278993Phase 2Completed
NCT00246090Phase 2Completed
NCT00097721Phase 2Completed
NCT00069264Phase 1Completed
NCT00069277Phase 1Completed

Competing Products

20 competing products in Soft Tissue Sarcoma

See all competitors